Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 protease inhibitors

被引:31
作者
Di Santo, R
Costi, R
Artico, M
Massa, S
Ragno, R
Marshall, GR
La Colla, P
机构
[1] Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy
[2] Univ Siena, Dipartimento Farm Chim Tecnol, I-53100 Siena, Italy
[3] Univ Roma La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biol At, I-00185 Rome, Italy
[4] Washington Univ, Ctr Mol Design, St Louis, MO 63110 USA
[5] Univ Cagliari, Dipartimento Biol Sperimentale, Sez Microbiol, I-09042 Cagliari, Italy
关键词
D O I
10.1016/S0968-0896(02)00119-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A series of N-aryl heteroarylisopropanolamines in which an indole or a 3-arylpyrrole moiety was linked to an aryl group through an isopropanolamine linker, were designed and synthesized as potential anti-HIV-1-PR agents. Series was tested for their ability in blocking PR activity. As a rule, indole derivatives of class I exhibited more potency than pyrrole analogues of class 2 while tert-butylamide substituents increased anti-PR potency. In fact, bis tert-butylamide le showed the highest activity with IC50 = 25 muM. Even if not very potent, a simple class of anti-PR agents, with a facile synthetic pathway was discovered. QSAR Studies on isopropanolamines I and 2 were performed in comparison with diarylbutanols, a new class of non peptidic anti-PR agents, recently discovered by Agouron Pharmaceuticals. QSAR and CoMFA models based on 30 diarylbutanols used as a training set were developed. The obtained models were used to investigate the binding mode of the newly synthesized derivatives I and 2. The results of this study suggest that N-aryl heteroarylisopropanolamines bind to the PR active site similarly to the diarylbutanols of Agouron. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2511 / 2526
页数:16
相关论文
共 28 条
[1]  
Appelt Krzysztof, 1993, Perspectives in Drug Discovery and Design, V1, P23, DOI 10.1007/BF02171654
[2]  
Artico M, 1996, FARMACO, V51, P305
[3]   GENERATING OPTIMAL LINEAR PLS ESTIMATIONS (GOLPE) - AN ADVANCED CHEMOMETRIC TOOL FOR HANDLING 3D-QSAR PROBLEMS [J].
BARONI, M ;
COSTANTINO, G ;
CRUCIANI, G ;
RIGANELLI, D ;
VALIGI, R ;
CLEMENTI, S .
QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS, 1993, 12 (01) :9-20
[4]   5,6-dihydropyran-2-ones possessing various sulfonyl functionalities: Potent nonpeptidic inhibitors of HIV protease [J].
Boyer, FE ;
Prasad, JVNV ;
Domagala, JM ;
Ellsworth, EL ;
Gajda, C ;
Hagen, SE ;
Markoski, LJ ;
Tait, BD ;
Lunney, EA ;
Palovsky, A ;
Ferguson, D ;
Graham, N ;
Holler, T ;
Hupe, D ;
Nouhan, C ;
Tummino, PJ ;
Urumov, A ;
Zeikus, E ;
Zeikus, G ;
Gracheck, SJ ;
Sanders, JM ;
VanderRoest, S ;
Brodfuehrer, J ;
Iyer, K ;
Sinz, M ;
Gulnik, SV ;
Erickson, JW .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (05) :843-858
[5]   AM1-SM2 AND PM3-SM3 PARAMETERIZED SCF SOLVATION MODELS FOR FREE-ENERGIES IN AQUEOUS-SOLUTION [J].
CRAMER, CJ ;
TRUHLAR, DG .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1992, 6 (06) :629-666
[6]   COMPARATIVE MOLECULAR-FIELD ANALYSIS (COMFA) .1. EFFECT OF SHAPE ON BINDING OF STEROIDS TO CARRIER PROTEINS [J].
CRAMER, RD ;
PATTERSON, DE ;
BUNCE, JD .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1988, 110 (18) :5959-5967
[7]   L-735,524 - THE DESIGN OF A POTENT AND ORALLY BIOAVAILABLE HIV PROTEASE INHIBITOR [J].
DORSEY, BD ;
LEVIN, RB ;
MCDANIEL, SL ;
VACCA, JP ;
GUARE, JP ;
DARKE, PL ;
ZUGAY, JA ;
EMINI, EA ;
SCHLEIF, WA ;
QUINTERO, JC ;
LIN, JH ;
CHEN, IW ;
HOLLOWAY, MK ;
FITZGERALD, PMD ;
AXEL, MG ;
OSTOVIC, D ;
ANDERSON, PS ;
HUFF, JR .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (21) :3443-3451
[8]   Optimizing the binding of fullerene inhibitors of the HIV-1 protease through predicted increases in hydrophobic desolvation [J].
Friedman, SH ;
Ganapathi, PS ;
Rubin, Y ;
Kenyon, GL .
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (13) :2424-2429
[9]   VALIDATE: A new method for the receptor-based prediction of binding affinities of novel ligands [J].
Head, RD ;
Smythe, ML ;
Oprea, TI ;
Waller, CL ;
Green, SM ;
Marshall, GR .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1996, 118 (16) :3959-3969
[10]   Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease [J].
Kaldor, SW ;
Kalish, VJ ;
Davies, JF ;
Shetty, BV ;
Fritz, JE ;
Appelt, K ;
Burgess, JA ;
Campanale, KM ;
Chirgadze, NY ;
Clawson, DK ;
Dressman, BA ;
Hatch, SD ;
Khalil, DA ;
Kosa, MB ;
Lubbehusen, PP ;
Muesing, MA ;
Patick, AK ;
Reich, SH ;
Su, KS ;
Tatlock, JH .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (24) :3979-3985